Showing 5211-5220 of 5621 results for "".
- Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-initiates-phase-1b-clinical-trial-of-topical-ocular-formulation-of-akb-9778-for-primary-open-angle-glaucoma/2476645/Aerpio Pharmaceuticals dosing of the first subject in a phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG). The phase 1 study is a double-masked, multiple-ascending dose trial and will enroll four cohorts of 12 subj
- OcuSoft Introduces NEW OcuSoft Lid Scrub Allergy Eyelid Treatment for Red, Itchy Allergy Eyeshttps://modernod.com/news/ocusoft-introduces-new-ocusoft-lid-scrub-allergy-eyelid-treatment-for-red-itchy-allergy-eyes/2476646/OcuSoft announced the availability of new OcuSoft Lid Scrub Allergy Eyelid Cleanser for allergy conditions in convenient pre-moistened pads. OcuSoft Lid Scrub Allergy removes oil, debris, pollen and other contaminants from the eyelids while utilizing Green Tea Extract, Tea Tree Oil and PSG
- Our Tears Could One Day Tell Us If We Have Glaucomahttps://modernod.com/news/our-tears-could-one-day-tell-us-if-we-have-glaucoma/2476643/Contrary to what many think, high pressure inside the eye does not define glaucoma and investigators want to know if the proteins circulating in the fluid of our eyes might, according to researchers at the Medical College of Georgia at Augusta University. While some patients do have classi
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- More Elderly Americans Dying From Fallshttps://modernod.com/news/more-elderly-americans-dying-from-falls/2476634/Death rates from falls are rising among elderly Americans and climbing fastest among seniors in their 90s, a US study suggests. Among all adults 75 and older, mortality from falls climbed 5.1% from 2000 to 2016, researchers report in JAMA. Death rates from falls rose the most—6.4%—among
- Pioneering Ophthalmologist Patricia Bath, MD, Dies at 76https://modernod.com/news/pioneering-ophthalmologist-patricia-bath-md-dies-at-76/2476632/Patricia E. Bath, MD, an ophthalmologist who took a special interest in combating preventable blindness in underserved populations and became the first black female doctor to patent a medical invention, a laser device for treating cataracts, died at the age of 76, acc
- Eyenovia Enrolls First Patient in Phase 3 CHAPERONE Study for Progressive Myopiahttps://modernod.com/news/eyenovia-enrolls-first-patient-in-phase-3-chaperone-study-for-progressive-myopia/2476629/Eyenovia announced that it has initiated its MicroPine phase 3 program with the first patient enrolled in its CHAPERONE study, a US-based, multicenter, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age. CHAPERO
- Allegro Ophthalmics Announces Positive Topline Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-announces-positive-topline-results-of-phase-2-study-evaluating-risuteganib-in-patients-with-intermediate-dry-amd/2476627/Allegro Ophthalmics announced positive topline results of its phase 2 study of risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD). The clinical trial met its primary endpoint with 48 percent of patients in the risuteganib arm gaining ≥ 8 letters of
- Re-Vana Therapeutics Names International Experts to Inaugural Scientific Advisory Boardhttps://modernod.com/news/re-vana-therapeutics-names-international-experts-to-inaugural-scientific-advisory-board/2476628/Re-Vana Therapeutics announced the formation of its new Scientific Advisory Board (SAB). The newly appointed SAB will strategically advise and support Re-Vana as it develops innovative therapies for a broad range of ophthalmic indications, including wet age-related macular degeneration (AMD), dia
- Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugshttps://modernod.com/news/verseon-showcases-oral-candidates-for-next-generation-diabetic-eye-disease-drugs/2476626/Verseon presented a new class of oral candidate drugs which could change the treatment and prevention of diabetic macular edema (DME). “Our oral development candidate, a novel inhibitor of plasma kallikrein, has the potential to redefine how DME is treated,” Dr. Anirban Datta, Verse